Seven vaccines have been approved, and the annual production capacity of my country's new crown vaccine reaches 5 billion doses

Tian Yulong, chief engineer of the Ministry of Industry and Information Technology, said at the press conference of the State Council Information Office on the 16th that the Ministry of Industry and Information Technology is guiding enterprises to accelerate the industrialization of the new crown vaccine and fully guarantee the domestic vaccination demand

Up to now, the annual production capacity of China's new crown vaccine has reached 5 billion doses, and the cumulative supply of domestic new crown vaccine has exceeded 1.

According to public data, there are currently 7 new crown vaccines in my country that have been approved for emergency use or marketed, and 22 new crown vaccines have entered clinical trials:

Vaccines approved in China

At present, the vaccines that have been approved for marketing are 5+1+1, that is, 5 inactivated vaccines, 1 adenovirus vector vaccine, and 1 recombinant protein vaccine

5 inactivated vaccines:

The Beijing Institute of New Coronary Inactivated Vaccine was put on the market conditionally on December 30, 2020, with a protection rate of 79.

Beijing Kexing's new coronavirus inactivated vaccine will be put on the market conditionally on February 5, 2021, with a protection rate of 50.

The Wuhan Institute of New Crown Inactivated Vaccine will be put on the market conditionally on February 25, 2021, with a protection rate of 72.

Kangtai biological inactivated vaccine was approved for domestic emergency use on May 14, 2021.

The inactivated vaccine from the Institute of Medical Biology of the Chinese Academy of Medical Sciences was approved for domestic emergency use on June 9, 2021, and the output will be expanded to 500 to 1 billion doses by the end of the year

Novo adenovirus vector vaccine:

The CanSino adenovirus vector vaccine will be put on the market conditionally on February 25, 2021, with a protection rate of 65.

Recombinant protein new crown vaccine:

Zhifei Bio-Recombinant Protein New Coronary Vaccine was approved for domestic emergency use on March 10, 2021.

The first domestic mRNA vaccine is about to be approved

On July 14, Fosun Pharma stated that the FDA's review of the mRNA new crown vaccine "Fubitai" (BNT162b2) has been basically completed, and the expert review has been passed

The administrative approval stage is currently being stepped up.

Follow-up key players

Watson Bio/Abbio's mRNA vaccine is currently in Phase 3 of overseas clinical trials

The recombinant protein vaccine of clover/CEPI/Dynavax is currently in clinical phase 2/3 phases worldwide

Livzumab's new crown vaccine V-01 is in phase II clinical trials